DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia

Clinical Epigenetics

Table 5 Clinical characteristics of ALL patients of known and newly classified subtype

Subtype	N (%) ^a	Sex M:F	Age median (range)	WBC median (range)	CNS, ^b n/y/u	CIR ^c	NOPHO protocol ^d				EsPhALL ^e	Infant ^f	Other/NA ^g
Subtype	N (%) ^a	Sex M:F	Age median (range)	WBC median (range)	CNS, ^b n/y/u	CIR ^c	SR	IR	HR	Ph+	EsPhALL ^e	Infant ^f	Other/NA ^g
T-ALL	101 (0.18)	2.9	9 (1–17)	138 (1–788)	89/12/0	0.20	0	2	86	1	0	0	12
T-ALL*	1 (0.00)	NA	11 (NA)	2 (NA)	1/0/0	0.00	0	0	1	0	0	0	0
HeH	189 (0.35)	1.2	3 (1–17)	9 (0–131)	187/2/0	0.16	82	79	22	0	0	0	6
HeH*	25 (0.12)	2.1	4 (1–14)	9 (1–91)	24/1/0	0.28	8	10	3	0	0	0	4
t(12;21)	161 (0.29)	1.1	4 (1–15)	14 (1–226)	159/0/2	0.22	68	65	24	0	0	0	4
t(12;21)*	33 (0.16)	1.1	4 (0–15)	11 (1–136)	33/0/0	0.24	12	11	6	0	0	1	3
11q23/MLL	27 (0.05)	0.7	0 (0–15)	193 (2–986)	25/1/0	0.41	0	1	11	0	0	14	1
11q23/MLL*	4 (0.02)	4.0	1 (0–1)	81 (38–1,255)	4/0/0	0.50	0	1	2	0	0	1	0
t(1;19)	21 (0.04)	0.8	11 (1–15)	35 (6–159)	20/1/0	0.14	0	3	17	0	0	0	1
t(1;19)*	15 (0.07)	0.9	7 (1–15)	10 (5–222)	14/1/0	0.07	1	9	3	0	0	0	2
dic(9;20)	20 (0.04)	0.4	2 (1–15)	50 (4–336)	19/1/0	0.25	4	5	10	0	0	0	1
dic(9;20)*	19 (0.09)	1.7	4 (1–18)	12 (1–164)	19/0/0	0.21	3	11	2	0	0	0	3
t(9;22)	19 (0.03)	2.2	10 (2–14)	61 (3–246)	17/2/0	0.47	0	0	1	6	12	0	0
t(9;22)*	5 (0.02)	4.0	12 (4–15)	102 (13–146)	5/0/0	0.40	0	0	1	0	0	0	4
iAMP21	8 (0.01)	7.0	9 (5–17)	5 (2–62)	8/0/0	0.38	2	3	1	0	0	0	2
iAMP21*	4 (0.02)	0.3	9 (7–16)	9 (4–23)	4/0/0	0.50	1	2	0	0	0	0	1
Multi-class	17 (0.03)	0.9	10 (3–17)	23 (1–106)	16/1/0	0.06	1	6	2	0	0	0	8
Non-class	83 (0.15)	1.5	9 (0–18)	20 (1–274)	80/3/0	0.23	13	30	25	0	0	3	11

*Patients with subtype determined by DNA methylation-based classification.
^aProportion of the total number of patients in the known subtype groups (n = 546) and newly classified patients (n = 210).
^bCentral nervous system involvement.
^cCumulative incidence of relapse (relapse as event of interest and other events as censoring).
^dNumber of patients treated on NOPHO-ALL treatment protocols.
^eNumber of patients treated according to the EsPhALL protocol.
^fNumber of patients treated according to the Interfant-99 or Interfant-06 protocols.
^gNumber of patients treated on other protocol or information not available.
Abbreviations: WBC white blood cell count at diagnosis, n/y/u no/yes/unknown, SR standard risk, IR intermediate risk, HR high risk, Ph + Philadelphia positive.

ISSN: 1868-7083